M06.89

M06.89 captures other specified rheumatoid arthritis affecting multiple joint sites simultaneously, used when the RA subtype does not carry a positive rheumatoid factor and the polyarticular presentation spans joints that cannot be collapsed into a single anatomic site code.

Verified May 8, 2026 · 9 sources ↓

Status: Billable
Chapter: 13
Related CPT: 10
Region: Multi-region

Drawn from CDCICD10DataAAPCNIHCMS

Documentation tips

What should appear in the chart to support M06.89.

Source · Editorial brief grounded in 9 cited references ↓

Name every joint region affected — wrists, MCPs, knees, ankles, etc. — so 'multiple sites' is clinically defensible and not confused with a vague unspecified diagnosis.
Document rheumatoid factor and anti-CCP serology results explicitly; a negative or absent RF is what keeps the encounter in the M06 block rather than M05.
If the RA subtype has a specific label (seronegative RA, adult-onset Still's disease, palindromic rheumatism), write that term — it justifies 'other specified' over M06.9 unspecified.
Record functional status, joint swelling, morning stiffness duration, and any imaging findings (erosions, joint space narrowing) to support medical necessity for biologics, DMARDs, or surgical referral.
When linking biologic infusion therapy (e.g., J-code HCPCS) to this diagnosis, the treatment authorization often requires documented disease activity scores such as DAS-28 or CDAI — include them in the note.

Related CPT procedures

Procedure codes commonly billed with M06.89. Linking the right diagnosis to the right procedure is what establishes medical necessity.

Source · CMS LCDs · AAOS specialty guidance · claims-pattern analysis

27447 $1,159.35

Knee replacement surgery addressing both the medial and lateral tibiofemoral compartments, with or without resurfacing of the patella.

27130 $1,162.02

Primary total hip arthroplasty replacing both the acetabular socket and proximal femoral components with prosthetic implants, with or without bone graft.

20610 $68.81

Aspiration and/or injection of a major joint or bursa (shoulder, hip, knee, or subacromial bursa) performed without ultrasound guidance.

20600 $56.11

Needle aspiration and/or injection of a small joint or bursa — such as a finger or toe joint — performed without ultrasound guidance.

97110 $29.06

Therapeutic exercise billed per 15-minute unit, targeting strength, endurance, range of motion, or flexibility with direct one-on-one patient contact.

73564 $49.43

Radiologic examination of the knee consisting of four or more views, including oblique and tunnel projections, for a complete diagnostic workup.

73221 $205.08

MRI of any upper extremity joint — shoulder, elbow, or wrist — performed without contrast material.

81490 View procedure details

86200 View procedure details

86235 View procedure details

Common coding pitfalls

The recurring mistakes coders make with M06.89 and adjacent codes.

Source · Editorial brief grounded in CDC ICD-10-CM tabular guidance, AAOS coding references, and cited references ↓

Routing seropositive RA to M06.89 instead of M05.89 — always check RF and anti-CCP results before selecting M06 over M05.
Defaulting to M06.9 (unspecified) when the provider has named specific joints; M06.89 is the correct choice whenever the joints are documented even if the combination has no single-site code.
Using M06.89 for a single-joint presentation — if only one joint is involved, a site-specific M06.8x code is required.
Failing to code concurrent systemic RA manifestations (e.g., rheumatoid lung, vasculitis, pericarditis) as secondary diagnoses, which can affect DRG weight and risk-adjustment scores.
Confusing M06.89 with M06.09 (Rheumatoid arthritis without rheumatoid factor, multiple sites) — M06.09 is the seronegative, unspecified-subtype code, while M06.89 requires a documented specific RA subtype.

Clinical context

Source · Editorial summary grounded in 9 cited references ↓

M06.89 sits under the M06.8 parent category ('Other specified rheumatoid arthritis') and is the terminal code for polyarticular involvement when the physician documents a specific RA variant — such as seronegative RA, adult-onset Still's disease overlap, or palindromic rheumatism — that does not fit the seropositive M05 series. Use it only when (1) the RA subtype is specified in documentation, (2) rheumatoid factor status is negative or not tested, and (3) two or more distinct joint regions are involved. If the chart documents a single anatomic site, use the appropriate site-specific M06.8x code instead (e.g., M06.821 for right elbow).

The critical fork in M06 coding is rheumatoid factor status. Seropositive RA with multiple-site involvement routes to M05.89 ('Other rheumatoid arthritis with rheumatoid factor of multiple sites'), not M06.89. Seronegative or RF-unspecified polyarticular RA lands in the M06 block. If documentation is vague and no joint specificity exists at all, M06.9 (rheumatoid arthritis, unspecified) is the fallback — but avoid it when clinical notes name the joints affected.

For inpatient DRG assignment, M06.89 groups to MS-DRG 545/546/547 (Connective Tissue Disorders with MCC/CC/without CC-MCC). Accurate capture of comorbidities and complications at the encounter directly shifts DRG weight, so secondary diagnoses tied to RA systemic involvement should be coded concurrently when documented.

Sibling codes

Other billable codes under M06.8 (laterality / anatomic variants).

M06.8A

Other specified rheumatoid arthritis, other specified site

M06.80

Other specified rheumatoid arthritis, unspecified site

M06.88

Other specified rheumatoid arthritis, vertebrae

Frequently asked questions

Source · Generated from the editorial pipeline, verified against 9 cited references ↓

01What is the difference between M06.89 and M06.09?

M06.09 is seronegative RA at multiple sites with no further subtype specified. M06.89 is used when the RA is both seronegative (or RF status unspecified) AND the physician documents a specific RA variant (e.g., seronegative RA, adult-onset Still's) that doesn't have its own dedicated code. In practice, M06.09 and M06.89 are often clinically adjacent; the presence of a specific subtype label in the note is what pushes you to M06.89.

02When should I use M06.89 instead of M05.89?

Use M05.89 when the patient has a documented positive rheumatoid factor or positive anti-CCP with multiple-site involvement. Use M06.89 when RF is negative or not documented and the RA subtype is otherwise specified. Serology status is the deciding variable.

03Can M06.89 be used if only two joints are affected?

Yes — 'multiple sites' means more than one anatomic joint region. Two distinct joint regions qualify. However, if both affected joints fall under a single site-specific M06.8x code, use that more granular code instead.

04Does M06.89 require laterality documentation?

No — M06.89 is a non-lateralized multiple-site code by design. The underlying site-specific M06.8x codes carry laterality (1 = right, 2 = left, 9 = unspecified), but M06.89 itself does not have sub-characters for side because it encompasses multiple joints.

05What DRGs does M06.89 map to for inpatient claims?

M06.89 groups to MS-DRG 545 (Connective Tissue Disorders with MCC), 546 (with CC), or 547 (without CC/MCC) under MS-DRG v43.0. Capturing documented comorbidities accurately shifts the DRG and directly affects reimbursement.

06Should I code biologic therapy separately when M06.89 is the primary diagnosis?

Yes. Biologic infusions and DMARDs are coded via CPT or HCPCS J-codes and should be linked to M06.89 as the supporting diagnosis. Payers often require documented disease activity scores (DAS-28, CDAI) in the clinical note to authorize these therapies, so ensure those scores appear in the encounter documentation.

07Is M06.89 valid for risk adjustment under CMS HCC models?

Yes. M06.89 maps to HCC 40 under CMS HCC Model V24, HCC 93 under V28, and RX-HCC 83 under RX-V08, reflecting the chronic, high-cost nature of polyarticular RA in risk-adjustment calculations.

Sources & references

Editorial content was developed using the following public sources. Last verified May 8, 2026.

Mira AI Scribe

Mira AI Scribe captures the specific joints named by the clinician, serology results (RF, anti-CCP), RA subtype terminology, and any documented systemic involvement — preventing the encounter from dropping to the less specific M06.9 or being miscoded to the seropositive M05.89 series. Missing any of these elements is the most common reason for payer audit flags and downcoded claims on polyarticular RA encounters.

See how Mira captures M06.89 documentation